Furthermore, we show that IL4I1, IDO1, or AHR high expression correlates with poorer survival of LGG patients, and that high IL4I1 expression also correlates with poorer outcome in GBM patients, confirming the clinical relevance of this pathway in these cancers. This evidence concerns the gene IDO1 and cancer.